Logo

NCNA

NuCana plc

NCNA

NuCana plc • NASDAQ
$4.28 ▲ 7.40% (+0.29)
Market Cap $25.99 M
52w High $330.00
52w Low $2.78
Dividend Yield 0%
P/E 0.01
Volume 78.60K
Outstanding Shares 6.07M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $779K ▼ $-281K ▲ 0% $-0.075 ▲ $-3.502M ▲
Q2-2025 $0 $11.829M ▲ $-24.114M ▼ 0% $-23.25 ▼ $-11.558M ▼
Q1-2025 $0 $2.851M ▲ $-2.473M ▼ 0% $-0.5 ▼ $-2.725M ▼
Q4-2024 $0 $865K ▼ $-653K ▲ 0% $-0.12 ▲ $-1.154M ▲
Q3-2024 $0 $5.323M $-4.511M 0% $-0.88 $-4.959M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $25.249M ▲ $32.315M ▲ $6.389M ▼ $25.926M ▲
Q2-2025 $8.443M ▲ $16.218M ▲ $8.834M ▲ $7.384M ▲
Q1-2025 $3.953M ▼ $11.601M ▼ $7.427M ▼ $4.174M ▼
Q4-2024 $6.749M ▼ $14.774M ▼ $8.82M ▼ $5.954M ▲
Q3-2024 $11.351M $19.534M $15.186M $4.348M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-281K ▲ $1.278M ▲ $64K ▲ $15.238M ▲ $16.806M ▲ $1.231M ▲
Q2-2025 $-24.114M ▼ $-4.486M ▼ $-28K ▼ $9.319M ▲ $4.49M ▲ $-4.543M ▼
Q1-2025 $-2.473M ▼ $-3.109M ▲ $-11K ▼ $442K ▼ $-2.796M ▲ $-3.148M ▲
Q4-2024 $-653K ▲ $-7.455M ▼ $22K ▲ $2.185M ▼ $-4.602M ▼ $-7.506M ▼
Q3-2024 $-4.511M $-4.603M $18K $4.676M $-288K $-4.666M

Five-Year Company Overview

Income Statement

Income Statement NuCana is still a pure research‑stage biotech with no product revenue, so all activity flows through as operating losses. These losses have been fairly steady over the last few years and look modest in size for a listed biotech, which suggests a relatively lean cost base but also a limited scope of operations. Earnings per share remain negative, reflecting ongoing R&D and overhead spending without offsetting income. In short, the income statement shows a company entirely focused on developing its pipeline, not yet on commercializing it.

Balance Sheet

Balance Sheet The balance sheet is small and mostly made up of cash, with no reported debt. Over the past several years, cash and total assets have been trending down as the company spends on trials, while equity has also eroded as losses accumulate. This is typical for a clinical‑stage biotech: the company is financially simple, but also increasingly dependent on future fundraising, partnerships, or positive trial outcomes to rebuild its capital base. The absence of debt gives flexibility, but the shrinking cash pile is a clear constraint.

Cash Flow

Cash Flow Cash flows show a consistent, relatively modest cash burn from operations and essentially no spending on physical assets, which fits a lab‑ and trial‑heavy biotech model. Free cash flow is negative every year, entirely driven by research and operating costs. The pattern is predictable but leaves the company reliant on its existing cash runway and future access to capital markets or partners. Management’s stated runway into late 2026, if achieved, buys time to reach key trial readouts, but there is little room for major unexpected setbacks without new financing.

Competitive Edge

Competitive Edge NuCana’s competitive edge comes from its proprietary ProTide technology, which is designed to make existing chemotherapy drugs more effective and better tolerated. This is a differentiated approach: rather than inventing entirely new mechanisms, it aims to upgrade proven drug classes. Strong patent coverage and a platform that can, in principle, be applied to many nucleoside chemotherapies support a defensible niche. However, the company is small, operates in a very crowded oncology market, and has already seen at least one trial discontinued for lack of expected benefit. Its position will ultimately depend on whether ongoing trials, especially in difficult‑to‑treat cancers, can show clearly better outcomes than current standards.

Innovation and R&D

Innovation and R&D Innovation is the core of NuCana’s story. Its ProTide platform chemically re‑engineers existing cancer drugs to enter tumor cells more effectively and avoid some resistance mechanisms. The R&D focus today is concentrated in a few key candidates: NUC‑7738, aimed at tough cancers like PD‑1–resistant melanoma (in combination with immunotherapy), and NUC‑3373, an upgraded version of a widely used chemotherapy backbone. Early and mid‑stage data show encouraging signs in some settings, but the termination of one colorectal cancer study underlines the trial‑and‑error nature of oncology R&D. Future value from R&D hinges on successful readouts from ongoing combination studies, expansion of ProTide applications to other drugs and tumors, and potential collaborations with larger pharma companies that can help push these programs through late‑stage trials and, if successful, to market.

Summary

Overall, NuCana looks like a classic early‑stage oncology biotech: no revenues, steady but controlled cash burn, and a balance sheet dominated by a gradually shrinking cash reserve and no debt. Financially, it is straightforward but dependent on external capital once the current runway is used. Strategically, its fate is tied to the success of a focused pipeline built on the ProTide platform, especially NUC‑7738 and, to a lesser degree, NUC‑3373. The technology offers a clear scientific rationale and a potentially scalable platform, but it operates in a highly competitive, high‑risk environment where one or two key trials can dramatically change the outlook. Investors and other observers would likely focus on clinical data flow, partnership activity, and funding plans as the main drivers of future outcomes.

NEWS

November 13, 2025 · 4:01 PM UTC

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 5, 2025 · 8:00 AM UTC

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Read more

September 5, 2025 · 8:00 AM UTC

NuCana Compliant with All Nasdaq Continued Listing Criteria

Read more

September 3, 2025 · 8:00 AM UTC

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Read more